The Rational Design of Genotoxins that Selectively Destroy Hormone Receptor-Positive Breast and Prostate Cancers SHAWN M. HILLIER,JOHN C. MARQUIS,KAUSHIK K. MITRA,PETER T. RYE,ARLETTE N. DINAUT,UDAY SHARMA,DENISE C. RODRIGUES,CHARLES I. MORTON,ROSA G. LIBERMAN,PAUL L. SKIPPER,JOHN S. WISHNOK,STEVEN R. TANNENBAUM,JOHN M. ESSIGMANN,AND ROBERT G. CROY,Department of Chemistry and Biological Engineering Division,Massachusetts Institute of Technology,Cambridge,Massachusetts 02139

Donahue, B.A. , M. Augot , S.F. Bellon , D.K. Treiber , J.H. Toney , S.J. Lippard , and J.M. Essigmann (1990). “Characterization of a DNA Damage-Recognition Protein from Mammalian Cells that Binds Specifically to Intrastrand d(GpG) and d(ApG) DNA Adducts of the Anticancer Drug Cisplatin.” Biochem 29: 5872—80.

Huang, J.C. , D.B. Zamble , J.T. Reardon , S.J. Lippard , and A. Sancar (1994). “HMG-Domain Proteins Specifically Inhibit the Repair of the Major DNA Adduct of the Anticancer Drug Cisplatin by Human Excision Nuclease.” Proc Natl Acad Sci USA 91: 10394—8.

Mitra, K. , J.C. Marquis , S.M. Hillier , P.T. Rye , B. Zayas , J.M. Essigmann , and R.G. Croy (2002). “A Rationally Designed Genotoxin that Selectively Destroys Estrogen Receptor Positive Breast Cancer Cells.” JACS 124(9): 1862—3.

Pil, P.M. and S. Lippard (1992). “Specific Binding of Chromosomal Protein HMG1 to DNA Damage by the Anticancer Drug Cisplatin.” Science 261: 234—7.

Rink, S.M. , K.J. Yarema , M.S. Solomon , L.A. Paige , B.M. Tadayoni-Rebek , J.M. Essigmann , and R.G. Croy (1996). “Synthesis and Biological Activity of DNA Damaging Agents that for Decoy Binding Sites for the Estrogen Receptor.” Proc Natl Acad Sci USA 91: 15063—8.

Treiber, D.K. , X. Zhai , H.M. Jantzen , and J.M. Essigmann (1994). “Cisplatin— DNA Adducts are Molecular Decoys for the Ribosomal RNA Transcription Factor hUBF (Human Upstream Binding Factor).” Proc Natl Acad Sci USA 91: 5672—6.